Navigation Links
Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that results available from its Phase 2 clinical trial of Hematide(TM) dosed monthly in dialysis patients were presented this week at the National Kidney Foundation (NKF) 2007 Spring Clinical Meeting. The results from this maintenance-switch trial in patients previously treated with three-times weekly Epoetin Alfa (EPO) demonstrated that mean hemoglobin (Hgb) levels can be maintained at clinically acceptable levels following a switch to once-monthly treatments with Hematide at an appropriate dosing regimen. The data were presented by Anatole Besarab, M.D., adjunct professor of Medicine, Wayne State University and director of Clinical Research at Henry Ford Hospital, Detroit in a poster session at the NKF meeting.

"These data are encouraging and show that patients can be switched from a regimen of EPO three-times weekly to once monthly Hematide in a controlled fashion where hemoglobin levels were maintained within 1 g/dL of baseline at an appropriate dosing regimen," said Dr. Besarab. This is especially important given the growing concerns related to excessive hemoglobin increases due to erythropoiesis stimulating agent use."

"We believe these data support the once per month dosing of Hematide and warrant further investigation in pivotal clinical studies," added Anne-Marie Duliege, M.D., vice president, Clinical, Medical and Regulatory Affairs at Affymax. "Based on the entire Phase 2 data set and as a result of our end of Phase 2 meetings with the Food and Drug Administration (FDA), we are preparing for Phase 3 clinical trials in patients on dialysis and not on dialysis. We are currently in discussions with the FDA on the design of this Phase 3 program."

The Phase 2 trial, which involved 165 patients, was an open label, multi-dose study conducted to assess safety, pharmacodynamics and pharmacokinetics of
'"/>




Page: 1 2 3

Related medicine technology :

1. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
2. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, ... medical device company developing its Symphony® CGM System ... today announced that Robert F. Doman , ... will present at "TEN", Noble Financial Capital Markets, ... Doman will make a corporate presentation to prospective ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... S.r.l. a full service and,leading clinical research organization (CRO), ... Research S.r.l., a CRO focused on Phase I to,Phase ... http://www.newscom.com/cgi-bin/prnh/20080122/335477 ) , ... and have legal and,operating offices in Milan, Italy. The ...
... DIO Rats Highlighted -PLYMOUTH MEETING, Pa., Jan. 22 ... GENR ) today announced a poster presentation ... drug candidate for the treatment of type 2 ... - Novel Aspects of the Regulation of Body ...
Cached Medicine Technology:Phidea Srl and Marvin Research Srl Announce Completion of Merger 2Phidea Srl and Marvin Research Srl Announce Completion of Merger 3Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 2Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... and Soothes Young Throats Now Available,Across the Northern ... cough and cold season,rapidly approaches, Integrated Beverage Group, ... products has launched its newest product,in Canada -- ... a perfect choice for parents who wish to,choose ...
... Company to Serve About 50,000 People Beginning February 1, ... AMERIGROUP,Corporation (NYSE: AGP ) announced today that the ... authorizing the Company,s Nevada subsidiary to,enter that State,s Medicaid ... 2009., The Nevada State Board of Examiners has ...
... lead to new treatments, researchers say , , WEDNESDAY, Nov. ... cells exhausted from fighting HIV infection has been discovered ... a molecule called Tim-3 is present at high levels ... HIV, the virus that causes AIDS. Blocking the activity ...
... Expertise to ... ... the,election of Jay Parsons to the company,s board of directors effective,immediately., ... programs and the development of customized incentive programs,that help consumers make ...
... likely to skip medicines, compared to whites , , WEDNESDAY, ... that included encouragement and occasional gifts improved medication adherence ... Americans with high blood pressure, a new study found. ... be nearly twice as likely to not take their ...
... That Demonstrate Best Strategic Use of Mergers ... ... Deal,( http://www.thedeal.com ) magazine has named Abbott,( http://www.abbott.com )as the healthcare ... honored Abbott for the,most effective strategic use of acquisitions and divestitures., ...
Cached Medicine News:Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 2Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 4Health News:Way to Rescue Tired Immune Cells Fighting HIV Found 2Health News:MedVantx(R) Names Newest Board Member 2Health News:Education Program Spurs Blacks to Take Blood Pressure Meds 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 3
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
... automated genetic analysis system. This system automatically ... linear polyacrylamide (LPA) gel, denatures and loads ... analyzes the data. Software tools let you ... automated data assessment. All to ensure unprecedented ...
ELISA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum...
Medicine Products: